These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24291713)

  • 1. A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge.
    Cheng C; Pal S; Tifrea D; Jia Z; de la Maza LM
    Microbes Infect; 2014 Mar; 16(3):244-52. PubMed ID: 24291713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis.
    Tifrea DF; Ralli-Jain P; Pal S; de la Maza LM
    Infect Immun; 2013 May; 81(5):1741-50. PubMed ID: 23478318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge.
    Pal S; Tifrea DF; Follmann F; Andersen P; de la Maza LM
    Vaccine; 2017 Mar; 35(13):1705-1711. PubMed ID: 28238632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors.
    Cheng C; Jain P; Bettahi I; Pal S; Tifrea D; de la Maza LM
    Vaccine; 2011 Sep; 29(38):6641-9. PubMed ID: 21742006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge.
    Pal S; Tatarenkova OV; de la Maza LM
    Immunology; 2015 Nov; 146(3):432-43. PubMed ID: 26423798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-delivery of amphipol-conjugated adjuvant with antigen, and adjuvant combinations, enhance immune protection elicited by a membrane protein-based vaccine against a mucosal challenge with Chlamydia.
    Tifrea DF; Pal S; Le Bon C; Giusti F; Popot JL; Cocco MJ; Zoonens M; de la Maza LM
    Vaccine; 2018 Oct; 36(45):6640-6649. PubMed ID: 30293763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the nine polymorphic membrane proteins of Chlamydia trachomatis for their ability to induce protective immune responses in mice against a C. muridarum challenge.
    Pal S; Favaroni A; Tifrea DF; Hanisch PT; Luczak SET; Hegemann JH; de la Maza LM
    Vaccine; 2017 May; 35(19):2543-2549. PubMed ID: 28385608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved protection against Chlamydia muridarum using the native major outer membrane protein trapped in Resiquimod-carrying amphipols and effects in protection with addition of a Th1 (CpG-1826) and a Th2 (Montanide ISA 720) adjuvant.
    Tifrea DF; Pal S; le Bon C; Cocco MJ; Zoonens M; de la Maza LM
    Vaccine; 2020 Jun; 38(28):4412-4422. PubMed ID: 32386746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.
    Sun G; Pal S; Weiland J; Peterson EM; de la Maza LM
    Vaccine; 2009 Aug; 27(36):5020-5. PubMed ID: 19446590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine.
    Carmichael JR; Pal S; Tifrea D; de la Maza LM
    Vaccine; 2011 Jul; 29(32):5276-83. PubMed ID: 21609745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with major outer membrane protein proteosomes elicits protection in mice against a Chlamydia respiratory challenge.
    Tifrea DF; Pal S; Toussi DN; Massari P; de la Maza LM
    Microbes Infect; 2013 Nov; 15(13):920-7. PubMed ID: 23999313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Encapsulation of Recombinant MOMP in Extended-Releasing PLGA 85:15 Nanoparticles Confer Protective Immunity Against a
    Sahu R; Dixit S; Verma R; Duncan SA; Smith L; Giambartolomei GH; Singh SR; Dennis VA
    Front Immunol; 2021; 12():660932. PubMed ID: 33936096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge.
    Pal S; Davis HL; Peterson EM; de la Maza LM
    Infect Immun; 2002 Sep; 70(9):4812-7. PubMed ID: 12183524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization.
    Ralli-Jain P; Tifrea D; Cheng C; Pal S; de la Maza LM
    Vaccine; 2010 Nov; 28(48):7659-66. PubMed ID: 20875490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Four Adjuvant Combinations, IVAX-1, IVAX-2, CpG-1826+Montanide ISA 720 VG and CpG-1018+Montanide ISA 720 VG, for Safety and for Their Ability to Elicit Protective Immune Responses in Mice against a Respiratory Challenge with
    Pal S; Slepenkin A; Felgner J; Huw Davies D; Felgner P; de la Maza LM
    Pathogens; 2023 Jun; 12(7):. PubMed ID: 37513710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.
    Tifrea DF; Pal S; Popot JL; Cocco MJ; de la Maza LM
    J Immunol; 2014 Jun; 192(11):5201-13. PubMed ID: 24778450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The
    Verma R; Sahu R; Dixit S; Duncan SA; Giambartolomei GH; Singh SR; Dennis VA
    Front Immunol; 2018; 9():2369. PubMed ID: 30374357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model.
    Hansen J; Jensen KT; Follmann F; Agger EM; Theisen M; Andersen P
    J Infect Dis; 2008 Sep; 198(5):758-67. PubMed ID: 18652549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a multisubunit recombinant polymorphic membrane protein and major outer membrane protein T cell vaccine against Chlamydia muridarum genital infection in three strains of mice.
    Yu H; Karunakaran KP; Jiang X; Brunham RC
    Vaccine; 2014 Aug; 32(36):4672-80. PubMed ID: 24992718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of intranasal and transcutaneous immunization for induction of protective immunity against Chlamydia muridarum respiratory tract infection.
    Skelding KA; Hickey DK; Horvat JC; Bao S; Roberts KG; Finnie JM; Hansbro PM; Beagley KW
    Vaccine; 2006 Jan; 24(3):355-66. PubMed ID: 16153755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.